INTRODUCTION
============

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that manifests during childhood and is characterized by attentional problems and/or hyperactivity-impulsivity in varying degrees of severity; it has a worldwide pooled prevalence of 5.29%.[@b1-cpn-14-184] ADHD is a chronic disorder that negatively affects several dimensions of life, particularly the academic, occupational, and social domains, during both childhood and adulthood.[@b2-cpn-14-184] In terms of its etiology, there are disruptions of the dopaminergic and noradrenergic pathways, which regulate attention, and an inhibition of executive function via alterations of the cortico--striato--thalamic--cortical networks.[@b3-cpn-14-184],[@b4-cpn-14-184]

The genetic heritability of ADHD ranges from 70% to 90%,[@b2-cpn-14-184],[@b5-cpn-14-184],[@b6-cpn-14-184] and a number of studies have investigated candidate genes that may contribute to the manifestation of ADHD. The catechol-*O*-methyltransferase (COMT) gene, which plays a role in the removal of dopamine (DA) from the synaptic space, is frequently studied as a possible candidate gene.[@b7-cpn-14-184] A single nucleotide polymorphism (SNP) of the COMT gene that includes a guanine (G) to adenine (A) mutation at codon 158 results in an amino acid substitution of methionine (met) for valine (val) during enzyme synthesis.[@b8-cpn-14-184] This polymorphism, which is known as either Val158Met or rs4680,[@b8-cpn-14-184] results in an enzyme with two Val alleles (val/val genotype) that is more thermostable[@b9-cpn-14-184] and degrades DA three-to-four times more rapidly than the two met isoforms (met/met genotypes) which, in turn, results in lower levels of DA in the synaptic space.[@b8-cpn-14-184]

Heterozygotes (val/met genotype carriers) are associated with intermediate levels of COMT activity,[@b10-cpn-14-184],[@b11-cpn-14-184] and healthy met/met genotype carriers exhibit superior performance in a number of cognitive paradigms, including the letter-number-sequencing test[@b12-cpn-14-184] and n-back task,[@b13-cpn-14-184] compared with individuals with the val/val genotype. The Val allele is related to decreased prefrontal cortical activation in healthy adults[@b14-cpn-14-184] and impaired working memory function in healthy adults and children.[@b14-cpn-14-184],[@b15-cpn-14-184] Cheon *et al*.[@b16-cpn-14-184] evaluated the association between the Val158met polymorphism and treatment response and found that the response to methylphenidate (Mph) was better in val/val genotype carriers than in carriers of other genotypes. However, Bellgrove *et al*.[@b17-cpn-14-184] observed that children with ADHD carrying the val/val genotype exhibited superior sustained attention than met carriers (met/met and val/met genotypes). On the other hand, studies of the relationship between the etiology of ADHD and polymorphisms of the COMT gene have reported equivocal results. For example, Kereszturi *et al*.[@b18-cpn-14-184] reported that the Val allele is more common in children with ADHD than in healthy controls, whereas other studies[@b19-cpn-14-184]--[@b21-cpn-14-184] and meta-analyses[@b22-cpn-14-184],[@b23-cpn-14-184] did not observe any type of relationship between these variables.

^1^H magnetic resonance spectroscopy (^1^H MRS) is a non-invasive neuroimaging technique that can be used in vivo to assess levels of neurometabolites, such as *N*-acety-laspartate (NAA), creatine (Cr), and choline (Cho), in a variety of brain areas. Courvoisie *et al*.[@b24-cpn-14-184] found higher levels of Cho in the prefrontal cortex (PFC) of children diagnosed with ADHD compared with healthy controls. Similarly, Husarova *et al*.[@b25-cpn-14-184] assessed children with ADHD during the second month of atomoxetine treatment and identified decreases in NAA levels and the NAA/Cr ratio in the left dorsolateral PFC (DLPFC) in conjunction with an increase in the Cho/Cr ratio in the right DLPFC. Amor[@b26-cpn-14-184] reported that drug-naïve children with a diagnosis of ADHD had lower Cho levels in the left PFC compared with healthy controls and ADHD children who had received treatment. A meta-analysis conducted by Aoki *et al*.[@b27-cpn-14-184] showed that, although the results of the adult ADHD patients and controls were similar, the NAA levels of ADHD-diagnosed children were higher than those of healthy controls in the medial PFC area. Thus, the present authors speculated that age-related changes in ADHD symptoms may have a neuronal basis even though no significant alterations in other metabolites have been reported.

Therefore, the present study utilized ^1^H MRS to investigate alterations in the neurometabolite levels of adult ADHD patients following a single dose of Mph according to the presence of the Val158met polymorphism of the COMT gene. To the best of our knowledge, the present study is the first to investigate pre- and post-Mph neurometabolite levels in adult ADHD patients based on this COMT polymorphism. It was hypothesized that different COMT gene polymorphism carriers would exhibit different treatment outcomes in terms of neurometabolite levels in different brain regions following a single dose of Mph.

METHODS
=======

Subject Characteristics
-----------------------

The present study assessed 57 adult patients who were between 18 and 60 years of age and who met the criteria of the Diagnostic and Statistical Manual of Mental Disorders 4th edition, text revision (DSM-IV-TR) for ADHD.[@b28-cpn-14-184] All patients were recruited from the psychiatry outpatient clinic of Pamukkale University in Turkey, and the absence of other psychiatric diagnoses was confirmed by structured interviews using the Turkish version of the Structured Clinical Interview for DSM-IV Clinical Version (SCID-I CV).[@b29-cpn-14-184] Additionally, the Turkish version of an adult attention-deficit disorder (ADD)/ADHD DSM-IV- based diagnostic screening and rating scale was used to assess the patients.[@b30-cpn-14-184] Patients with a neurodegenerative disorder, such as Alzheimer's disease or Parkinson's disease, and/or a clinical evaluation of an intellectual disability were excluded from the present study. The local Ethics Committee of Pamukkale University approved the study protocol (approval no. 60116787/020/27537), and all patients were informed of the aim of the study and its procedures; all patients also provided written informed consent confirming their voluntary participation in this study.

All patients were examined with a single-voxel ^1^H MRS, and the spectra were obtained from the DLPFC, anterior cingulate cortex (ACC), striatum, and cerebellum via a clinical 1.5-T magnetic resonance scanner (GE Medical System, Milwaukee, WI, USA). For this procedure, the following parameters were employed: a point-resolved spectroscopy sequence with water suppression, a chemical shift selective imaging sequence, an echo time (TE)/repetition time (TR) ratio of 35/3,000 ms, and 128 averages. Additionally, the present study utilized a conventional spin-echo sequence with T2-weighted fast spin-echo parameters as follows: horizontal slices (10-mm thick), a TR/TE ratio of 3,000/88 ms, a field of view of 10 cm, and a 512×512 matrix. The entire MR session took approximately 45 minutes to complete.

Patients who had been previously been administered Mph discontinued their use of the medication 48 hours prior to the initiation of the neuroimaging procedures. The levels of NAA, Cho, and Cr in the DLPFC, ACC, striatum, and cerebellum were examined using single-voxel ^1^H MRS when the patients were medication-naïve 30 minutes after the administration of Mph (10 mg).

Genotypic Analysis of the Val158Met (c.1947, G\>A, rs4680) Polymorphism of the COMT Gene
----------------------------------------------------------------------------------------

### DNA extraction

A venous blood sample was obtained from each individual and collected in a tube containing ethylene-diaminetetraacetic acid. The DNA was extracted from the whole blood using a previously described salting-out procedure.[@b31-cpn-14-184]

### Genotype determination

The genotypes were determined using a TaqMan™ fluorogenic 5′-nuclease assay and TaqMan probes (Applied Biosystems, Framingham, MA, USA). The Primer Express 3.0 software package (Applied Biosystems) was used to design both the polymerase chain reaction (PCR) primers and the TaqMan probes. The following custom- made primers and probes were used for the COMT gene 1947 G\>A Val158Met (rs4680) allele; forward primer: 5′-CATCACCCAGCGGATGGT-3′, reverse primer: 5′-TCAGGCATGCACACCTTGTC-3′, probe: (A)5′-VIC- ATTTCGCTGGCATGAA-NFQ-MGB-3′, and probe: (G) 5′-FAM-ATTTCGCTGGCGTGAA-NFQ-MGB-3′ (Applied Biosystems).

The SNP amplification assays were performed according to the manufacturer's instructions (Applied Biosystems). Briefly, 25 *μ*l of the reaction solution that contained 30 ng of DNA was mixed with 12.5 *μ*l of 2× TaqMan Universal PCR Master Mix (Applied Biosystems), 900 nmol of each primer, and 200 nmol of each probe. The reaction conditions were as follows: pre-incubation at 60°C for 1 minute, incubation at 95°C for 10 minutes, 40 cycles at 95°C for 15 seconds, and then incubation at 60°C for 1 minute. The amplifications and analyses were performed using an ABI Prism 7500 Real-Time PCR System (Applied Biosystems) with the SDS software package (ver. 2.0.6; Applied Biosystems) for allelic discrimination.[@b31-cpn-14-184]

Statistical Analysis
--------------------

All data were analyzed using the SPSS for Windows software package (ver. 17.0; SPSS Inc., Chicago, IL, USA). Categorical variables were compared using Pearson's chi-square (*χ*^2^) tests, and the distribution of the numeric variables was evaluated using the Kolmogorov- Smirnov test. Nonparametric tests were used because the variables were not distributed normally. Kruskal-Wallis tests were used to make comparisons among the three groups, and Mann-Whitney *U*-tests were used to compare the data between two groups. Significant differences in the changes in neurometabolite levels prior to and after treatment with Mph were assessed with the Wilcoxon two-related-samples test, and a *p* value \<0.05 was considered to indicate statistical significance.

RESULTS
=======

Of the 57 adult ADHD patients assessed in the present study, 12 were female (21.1%) and 45 were male (78.9%); all were between 18 and 60 years of age (mean age, 29.05±7.85 years). However, only 33 (57.9%) of the patients had been receiving Mph for the treatment of ADHD ([Table 1](#t1-cpn-14-184){ref-type="table"}).

The COMT polymorphism and ADHD subtype distributions of the patients are shown in [Table 2](#t2-cpn-14-184){ref-type="table"}. The distribution of the three genotypes for the COMT gene was in agreement with the expected values of the Hardy- Weinberg equilibrium (*p*=0.888). The majority of the patient group (80.7%; n=46) were val carriers (val/val, val/met), that is, rapid metabolizers. There were no significant differences in the distributions of the ADHD subtypes according to COMT polymorphism (*χ*^2^=4.29, *p*=0.29; [Table 2](#t2-cpn-14-184){ref-type="table"}). In total, 37 of the males (82.2%) and nine of the females (75.0%) were val carriers, but there was no significant difference in the gender distribution according to COMT polymorphism (*χ*^2^=0.31, *p*=0.57).

For the metabolic assessments, the patients were categorized according to the COMT polymorphisms in two different ways, and all statistical analyses were performed accordingly. For the first categorization, the patients were divided into three groups (val/val, val/met, and met/met genotype carriers) and their neurometabolic variables were compared. For the second categorization, the patients were divided into two groups: val genotype carriers (val/val and val/met; i.e., rapid metabolizers) and met/met genotype carriers (slow metabolizers). After a single 10-mg dose of Mph, there was a significant increase in NAA levels in the DLPFC of the val/val genotype carriers (*p*=0.04) and the ACC of the val carriers (*p*=0.03; [Table 3](#t3-cpn-14-184){ref-type="table"} and [Fig. 1](#f1-cpn-14-184){ref-type="fig"}). The pre-Mph NAA/Cr ratio was significantly lower in the DLPFC of val carriers than that in the met/met genotype carriers (*p*=0.02), but there were no significant post-Mph alterations in NAA levels or NAA/Cr ratios in the other brain regions that were investigated. Cho levels in the striatum of the val/met and val genotype carriers significantly increased after a single dose of Mph compared with pre-medication levels (*p*=0.01 and *p*=0.007, respectively). However, there were no significant medication-related changes in Cho levels in the other brain regions based on polymorphism ([Table 3](#t3-cpn-14-184){ref-type="table"} and [Fig. 1](#f1-cpn-14-184){ref-type="fig"}). Although the pre-medication Cr levels in the DLPFC were similar in all groups, after Mph treatment there were higher Cr levels in the met/met genotype carriers than in the val/met and val carriers (*p*=0.01 and *p*=0.03, respectively; [Table 3](#t3-cpn-14-184){ref-type="table"}). Consistent with these findings, the Cr levels in the DLPFC of the met/met genotype carriers significantly increased after a single dose of Mph compared with their pre-medication levels (*p*=0.01; [Table 3](#t3-cpn-14-184){ref-type="table"} and [Fig. 2](#f2-cpn-14-184){ref-type="fig"}). In the val/val genotype carriers, Cr levels in the striatum significantly decreased after Mph treatment (*p*=0.01), but the Cr levels in the other brain regions were not affected ([Table 3](#t3-cpn-14-184){ref-type="table"}).

DISCUSSION
==========

Of the 57 adult ADHD patients assessed in the present study, the number of rapid metabolizers (val carriers; n=46) was approximately fourfold higher than that of slow metabolizers (met/met genotype; n=11). The Val allele enhances the hypodopaminergic state in the synaptic space to a greater degree than the Met allele due to its thermostability,[@b9-cpn-14-184] and healthy met/met genotype carriers exhibit superior cognitive performance compared with val/val genotype carriers.[@b12-cpn-14-184],[@b13-cpn-14-184] Similarly, the Val allele has a stronger association with impaired working memory function than does the Met allele in healthy adults and children,[@b14-cpn-14-184],[@b15-cpn-14-184] and it is also associated with decreased pre-frontal cortical activation in healthy adults.[@b14-cpn-14-184] In contrast to these findings, other studies[@b24-cpn-14-184],[@b32-cpn-14-184] and meta-analyses[@b22-cpn-14-184],[@b23-cpn-14-184] have reported no relationship between ADHD and COMT gene polymorphisms.

The predominance of val carriers in the present patient group appears to support the Val allele-ADHD relationship in terms of disease etiology. The conflicting reports from several candidate gene studies may be due to the multigenic and multifactorial etiology of ADHD because, although the COMT polymorphism may affect the development of ADHD, this does not occur in isolation. To better understand this relationship, ADHD-related networks and other factors (particularly catecholamine-related polymorphisms) that may have an impact on the development of ADHD should be researched on a larger scale. Consistent with the results of Yatsuga *et al*.,[@b32-cpn-14-184] the present study did not find a relationship between ADHD subtype and COMT polymorphism. It is possible that the contribution of the COMT polymorphism to ADHD is not subtype-specific or it could be that the small sample size used in the present study may have influenced the present results.

NAA
---

Following treatment with Mph, there was a significant increase in the amount of NAA in the DLPFC of the val/val genotype carriers and in the ACC of the val carriers. In contrast, Carrey *et al*.[@b33-cpn-14-184] did not find any significant alterations in the neurometabolite levels in the right frontal region of ADHD patients after 13 weeks of treatment with atomoxetine, Mph, or Dexedrine. Husarova *et al*.[@b25-cpn-14-184] reported that the NAA levels and NAA/Cr ratio decreased in the left DLPFC of ADHD patients after 2 months of atomoxetine treatment, but that there were no significant alterations after treatment with Mph. A meta- analysis revealed that the amount of NAA in the medial PFC of children with ADHD was significantly higher than that of the controls, but this difference declined with age and disappeared in adults, which suggests that age-related alterations in ADHD symptoms may have a neuronal basis.[@b34-cpn-14-184]

In this respect, the present findings disagree with those of previous studies. NAA is considered to be a marker of regional neuronal activation and vitality,[@b35-cpn-14-184] and neuroimaging studies conducted among ADHD patients have observed numerous alterations of this metabolite in various brain regions, principally the PFC, ACC, and striatum.[@b36-cpn-14-184] Compared with healthy controls, ADHD patients show reduced perfusion, especially in the PFC,[@b37-cpn-14-184],[@b38-cpn-14-184] and a study investigating the effects of treatment on hypoperfusion found that stimulant medication increases blood flow in the bilateral prefrontal, caudate, and thalamic areas.[@b38-cpn-14-184] Similarly, the chronic administration of Mph increases neuronal mitochondrial activity in rats,[@b39-cpn-14-184] and a single dose of Mph can lead to increases in neuronal activation in the frontal lobes of patients with ADHD.[@b40-cpn-14-184]

Taken together, these data suggest that Mph has a positive impact on impaired cerebral perfusion and neuronal function. Therefore, post-Mph increases in NAA levels may indicate improved perfusion and increased neuronal activation, as in the present data. As suggested by Angelie *et al*.,[@b41-cpn-14-184] the contrasting results among studies may be due to the presence or absence of a cognitive performance measure during the assessment process and, more importantly, they may be related to age, sex, the investigated regions, or related variations in NAA levels.

NAA/Cr Ratio
------------

In the present study, the pre-Mph NAA/Cr ratio in the DLPFC of val carriers was significantly lower than that of the met/met genotype carriers. During the literature search for this study, it became clear that no previous studies had investigated the relationship between the NAA/Cr ratio and COMT polymorphisms. Jin *et al*.[@b42-cpn-14-184] reported a lower NAA/Cr ratio in the striatum of children with ADHD relative to that of healthy controls, and this did not change after a single 10-mg dose of Mph. In contrast, Fayed *et al*.[@b43-cpn-14-184] found that the prefrontal cortico-subcortical NAA/Cr ratio is higher in ADHD children than in healthy controls, and Wiguna *et al*.[@b44-cpn-14-184] reported a significantly increase in the NAA/Cr ratio in the bilateral PFC of ADHD patients after 12 weeks of Mph treatment. Contradictory results in the literature may be due to changes in NAA levels according to age, sex, and the brain area investigated.

The NAA/Cr ratio is a marker of brain maturation.[@b45-cpn-14-184] Childhood ADHD is related to delayed cortical maturation, especially in the PFC.[@b4-cpn-14-184] Furthermore, adult studies have demonstrated the presence of decreased gray matter and reduced cortical thickness in ADHD patients compared with controls.[@b46-cpn-14-184],[@b47-cpn-14-184] It is known that cortical thickness is related to disease severity.[@b47-cpn-14-184] The number of Val alleles in ADHD patients is associated with the rate at which DA is metabolized[@b9-cpn-14-184]--[@b11-cpn-14-184] and, therefore, it is also related to disease severity. This indicates that the present finding that val carriers have a lower NAA/Cr ratio (a maturation marker) than the met/met genotype carriers is intuitive.

Cho
---

Cho levels significantly increased in the striatum of the val and val/met genotype carriers following treatment with Mph compared with pre-medication levels. To the best of our knowledge, no studies have investigated the relationship between Cho levels in ADHD patients and COMT polymorphisms. A number of studies have assessed Cho metabolites in ADHD patients and produced variable results. Similar to the present findings, Carrey *et al*.[@b33-cpn-14-184] did not find any treatment-related changes in Cho levels in the PFC of ADHD children. However, this negative result in the striatal area contrasts with the findings of the present study. Kronenberg *et al*.[@b48-cpn-14-184] found a significant decrease in the Cho levels in the ACC of adult ADHD patients after 5--6 weeks of Mph treatment. In a study conducted by Amor,[@b26-cpn-14-184] lower levels of Cho were reported in the left prefrontal area of treatment-naïve ADHD patients compared with both treatment-receiving ADHD children and healthy controls. Jin *et al*.[@b42-cpn-14-184] reported a marginal increase in the Cho/Cr ratio in the striatum of children with ADHD, but a single 10-mg dose of oral Mph had no effect on these ratios. The authors speculated that this could account for approximately 20--25% of the neural loss and/or dysfunction observed in ADHD patients.

Cho is found in the cellular membrane and is an indicator of lipid metabolism and membrane integrity.[@b49-cpn-14-184] It should also be noted that Cho is an acetylcholine precursor that influences neural communication and is mediated by various neurotransmitters, including norepinephrine and DA. It has been suggested that impairments in dop-aminergic pathways, as well as the imbalances in the dop-aminergic-cholinergic system that are seen in ADHD, may affect Cho levels.[@b42-cpn-14-184] With respect to previous studies, these differences may be related to medication type, treatment duration and dose, and variations in the genetic structure of the recruited individuals. However, 57.9% of the present patients were medicated with Mph and, therefore, the data may have been influenced by drug-induced effects on neuroplasticity.

Cr
--

Following the administration of Mph in the present study, Cr levels in the DLPFC were significantly higher in the met/met genotype carriers than in the val/met genotype carriers and val carriers. In accordance with this result, Cr levels significantly increased in the DLPFC of met/met genotype carriers after Mph treatment compared with pre-Mph levels, whereas the striatal Cr levels in val/val genotype carriers significantly decreased after Mph treatment.

To the best of our knowledge, the Cr levels of ADHD patients have yet to be assessed according to COMT polymorphisms, and studies investigating variability in pre- and post-Mph Cr levels in ADHD patients have reported contrasting results. Yang *et al*.[@b50-cpn-14-184] observed lower Cr and phospho-Cr levels in the right PFC of ADHD patients compared with healthy controls, whereas a meta-analysis revealed no difference in medial PFC Cr levels between ADHD and control groups.[@b27-cpn-14-184] Consistent with the present results, Kronenberg *et al*.[@b48-cpn-14-184] did not find any significant differences in pre- and post-treatment Cr levels in the ACC of adult ADHD patients after 5--6 weeks of Mph administration.

Cr and phospho-Cr are accepted indicators of energy metabolism in neurons and astrocytes. Therefore, decreased levels of these parameters indirectly signify impaired neuronal activity and function.[@b51-cpn-14-184] In the present study, val genotype carriers had lower prefrontal Cr levels than met/met genotype carriers, which supports the energetic hypothesis of ADHD[@b49-cpn-14-184] and is consistent with the val amino acid-associated hypo-dopaminergic state observed in ADHD patients.[@b9-cpn-14-184] Following Mph treatment, there was a significant increase in Cr levels in the PFC of the met/met genotype carriers, which indicates that there was an increase in neuronal activity following treatment-related improvements in hypoperfusion. In another study, baseline striatal Cr levels were reportedly higher in ADHD children than in controls after 8 weeks of treatment and, similar to the present findings, striatal Cr levels significantly decreased.[@b52-cpn-14-184] The authors speculated that stimulant treatment might increase monoamine availability and striatal Cr within the context of a phospho-Cr-dependent uptake of glutamate into synaptic vesicles. Therefore, decreased post-medication Cr levels in the striatum may represent a compensatory mechanism.[@b52-cpn-14-184]

It should be noted that approximately half the participants in the present study had previously used Mph for the treatment of ADHD. Previous data have shown that chronic stimulant use influences the activities of neuro-transmitter systems and brain plasticity, including synaptic and non-synaptic levels.[@b53-cpn-14-184],[@b54-cpn-14-184] Despite contradictory findings,[@b40-cpn-14-184],[@b55-cpn-14-184] neuroimaging studies have demonstrated that Mph predominantly acts in the frontal cortex, basal ganglia (including the striatum), ACC, and cerebellum in ADHD patients and that psychostimulant medications generally normalize ADHD-related hypoactivation in these areas.[@b54-cpn-14-184],[@b55-cpn-14-184] Studies investigating the effects of psychostimulants on the brains of ADHD patients indicate that these medications cause structural and developmental changes in important brain regions, such as the cerebellar vermis,[@b56-cpn-14-184] ACC,[@b57-cpn-14-184] and basal ganglia.[@b58-cpn-14-184] Conversely, this type of medication is not related to the slowed growth of the cortical mantle in ADHD patients.[@b59-cpn-14-184] Similarly, volume abnormalities in the cerebrum and cerebellum of ADHD patients are consistently identified across the childhood and adolescent periods, and these changes are not associated with medication use.[@b60-cpn-14-184] In light of these data, it can be suggested that the present findings might have been affected by the previous use of Mph, even though Mph treatment was discontinued 48 hours prior to the neuroimaging to minimize its effect on neurometabolites. This may have prevented the identification of significant findings specifically related to the cerebellum due to the effects of chronic Mph use on the cerebellum. Thus, future studies are needed to evaluate the effects of Mph among ADHD patients who are drug-naïve.

It is also important to mention that neurometabolite levels, particularly NAA, are affected by age[@b27-cpn-14-184],[@b41-cpn-14-184] and clinical presentation[@b61-cpn-14-184] and that the neurobiological basis of ADHD changes with age.[@b27-cpn-14-184],[@b34-cpn-14-184] Therefore, the wide age range of the present sample may have affected the present results, which makes generalizing these findings difficult.

There are several limitations to the present study. Approximately half the patients had already used Mph for the treatment of ADHD, and cigarette use, which may change the response to Mph, was not utilized as an exclusion criterion. In the present study, a low Tesla MR scanner was used, and only unilateral brain assessments were conducted. Additionally, the sample size was relatively small, no control group was included, and the wide age range of the patients decreases the generalizability of the results. Finally, although the patients were evaluated using adult ADD/ADHD DSM-IV-based diagnostic screening and rating scales prior to the administration of Mph, there were no assessments of treatment outcomes following the administration of the drug.

The present study assessed the effects of single-dose Mph on three different neurometabolites in adult ADHD patients who were categorized according to COMT polymorphism. As expected, there was a predominance of val carriers (rapid metabolizers) among the patients. Pre- and post-medication changes in neurometabolite levels were detected in certain brain areas in accordance with COMT polymorphisms, which suggests that COMT gene polymorphisms can account for individual differences in the neurochemical response to Mph in ADHD patients. The present study provides important contributions to the literature, because it is the first to investigate the effects of single-dose Mph on neurometabolite levels according to COMT polymorphisms.

To better understand the neuropathology of ADHD, further research using drug-naïve patients, larger sample sizes, and higher-resolution neuroimaging methods is required. Additionally, the effects of age and sex should be minimized, control groups should be included, and the specific effects of the COMT val158met polymorphism on treatment outcomes in ADHD patients should be analyzed.

The authors thank Ayse Gonca Unal for her contribution during the patient recruitment phase.

![Values of neurometabolites before and after methylphenidate in Val carriers (rapid metabolizers).\
DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex; CB, cerebellum; STR, striatum; NAA, *N*-acetylaspartate; Cho, choline; Cr, creatinine.\
\*Before methylphenidate, ^†^after methylphenidate.](cpn-14-184f1){#f1-cpn-14-184}

![Values of neurometabolites before and after methylphenidate in met/met genotypes (slow metabolizers).\
DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex; CB, cerebellum; STR, striatum; NAA, *N*-acetylaspartate; Cho, choline; Cr, creatinine.\
\*Before methylphenidate, ^†^after methylphenidate.](cpn-14-184f2){#f2-cpn-14-184}

###### 

Sociodemographic characteristics

  Characteristic        Data
  --------------------- -----------
  Sex                   
   Female               12 (21.1)
   Male                 45 (78.9)
  Marital status        
   Single               35 (61.4)
   Married              18 (31.6)
   Divorced             4 (7.0)
  Education             
   Primary education    5 (8.8)
   High school          12 (21.1)
   University           40 (70.1)
  Methylphenidate use   
   Yes                  33 (57.9)
   No                   24 (42.1)

Values are presented as number (%).

###### 

ADHD subtypes and the COMT gene polymorphism

                                   COMT gene polymorphism               
  -------------------------------- ------------------------ ----------- -----------
  Attention deficit type           9 (45.0)                 8 (40.0)    3 (15.0)
  Hyperactivity impulsivity type   5 (55.6)                 3 (33.3)    1 (11.1)
  Combined type                    6 (21.4)                 15 (53.6)   7 (25.0)
  Total                            20 (35.1)                26 (45.6)   11 (19.3)

Values are presented as number (%).

ADHD, attention deficit hyperactivity disorder; COMT, catechol-*O*-methyltransferase.

*p*=0.29, *X*^2^=4.29; by chi-square test.

###### 

Comparison of the neurometabolites between the COMT gene Val158Met polymorphism groups

                                                               Val/val                                                   Val/met                                                   Met/met                                                                                             *p* value[\*](#tfn8-cpn-14-184){ref-type="table-fn"}   *p* value[†](#tfn9-cpn-14-184){ref-type="table-fn"}
  ----------------------------------------------- ------------ --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------ -----------------------------------------------------
  Comparison of NAA levels before and after Mph                                                                                                                                                                                                                                                                                               
   DLPFC                                          Before Mph   68 (50--117)[†](#tfn9-cpn-14-184){ref-type="table-fn"}    66 (45--98)                                               74 (53--107)                                                                                        0.486                                                  0.04[†](#tfn9-cpn-14-184){ref-type="table-fn"}
                                                  After Mph    71 (51--115)[†](#tfn9-cpn-14-184){ref-type="table-fn"}    59.5 (39--92)                                             70 (60--113)                                                                                        0.097                                                  
   ACC                                            Before Mph   62.5 (51--126)                                            58 (39--87)                                               66 (51--83)                                                                                         0.174                                                  
                                                  After Mph    68.5 (54--113)                                            63 (47--94)                                               62 (56--79)                                                                                         0.225                                                  
   Striatum                                       Before Mph   63.5 (50--97)                                             62 (45--82)                                               61 (52--76)                                                                                         0.684                                                  
                                                  After Mph    67 (45--94)                                               59 (45--85)                                               68 (55--105)                                                                                        0.146                                                  
   Cerebellum                                     Before Mph   61 (38--96)                                               60.5 (31--78)                                             57 (37--89)                                                                                         0.724                                                  
                                                  After Mph    66 (38--85)                                               60.5 (38--84)                                             61 (52--88)                                                                                         0.521                                                  
  Comparison of Cho levels before and after Mph                                                                                                                                                                                                                                                                                               
   DLPFC                                          Before Mph   41 (26--66)                                               38 (29--62)                                               37 (26--52)                                                                                         0.196                                                  
                                                  After Mph    42 (29--70)                                               39.5 (26--62)                                             40 (36--51)                                                                                         0.170                                                  
   ACC                                            Before Mph   38.5 (24--65)                                             37 (25--50)                                               38 (22--54)                                                                                         0.945                                                  
                                                  After Mph    41 (24--44)                                               37.5 (26--52)                                             35 (32--48)                                                                                         0.405                                                  
   Striatum                                       Before Mph   36 (24--53)                                               33 (22--45)[†](#tfn9-cpn-14-184){ref-type="table-fn"}     36 (28--55)                                                                                         0.239                                                  0.01[†](#tfn9-cpn-14-184){ref-type="table-fn"}
                                                  After Mph    36.5 (27--57)                                             35.5 (27--56)[†](#tfn9-cpn-14-184){ref-type="table-fn"}   36 (26--47)                                                                                         0.929                                                  
   Cerebellum                                     Before Mph   45.5 (31--61)                                             40.5 (25--51)                                             45 (25--59)                                                                                         0.196                                                  
                                                  After Mph    41 (27--64)                                               41.5 (29--56)                                             44 (31--64)                                                                                         0.492                                                  
  Comparison of Cr levels before and after Mph                                                                                                                                                                                                                                                                                                
   DLPFC                                          Before Mph   40 (29--70)                                               40.5 (29--53)                                             39 (28--55)[†](#tfn9-cpn-14-184){ref-type="table-fn"}                                               0.804                                                  0.01[†](#tfn9-cpn-14-184){ref-type="table-fn"}
                                                  After Mph    43 (33--69)                                               39 (23--60)[\*](#tfn8-cpn-14-184){ref-type="table-fn"}    42 (38--66)[\*](#tfn8-cpn-14-184){ref-type="table-fn"},[†](#tfn9-cpn-14-184){ref-type="table-fn"}   0.018[\*](#tfn8-cpn-14-184){ref-type="table-fn"}       
   ACC                                            Before Mph   41.5 (29--73)                                             40.5 (30--57)                                             43 (36--49)                                                                                         0.357                                                  
                                                  After Mph    44 (31--69)                                               42.5 (33--62)                                             43 (34--55)                                                                                         0.591                                                  
   Striatum                                       Before Mph   47.5 (36--69)[†](#tfn9-cpn-14-184){ref-type="table-fn"}   42 (29--51)                                               46 (38--59)                                                                                         0.054                                                  0.01[†](#tfn9-cpn-14-184){ref-type="table-fn"}
                                                  After Mph    43 (34--66) [†](#tfn9-cpn-14-184){ref-type="table-fn"}    41.5 (34--58)                                             48 (36--61)                                                                                         0.463                                                  
   Cerebellum                                     Before Mph   53 (24--70)                                               49 (34--66)                                               54 (29--65)                                                                                         0.396                                                  
                                                  After Mph    52 (27--74)                                               52.5 (27--65)                                             55 (41--74)                                                                                         0.542                                                  

Values are presented as median (range).

COMT, catechol-*O*-methyltransferase; DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex; Mph, methylphenidate; NAA, *N*-acetylaspartate; Cho, choline; Cr, creatine.

By

Kruskal Wallis test and

two related sample test (Wilcoxon).

[^1]: These authors contributed equally to this study.
